To achieve an affordable price for its advanced cancer test, Delphi prioritizes algorithmic complexity over "wet lab" complexity. This strategy keeps physical sample processing simple and low-cost, putting the innovation into scalable software (AI/ML) to analyze the data, which is key for mass adoption.

Rather than spreading multi-cancer detection platforms across several indications simultaneously, startups reduce adoption uncertainty by focusing on underserved patient groups. Targeting conditions with painful, overused standard diagnostic procedures creates immediate clinical demand and clear pathways to adoption.

There is a profound mismatch between the critical role of diagnostics in guiding medical treatment and their reimbursement value. This value gap highlights a systemic inefficiency and a major opportunity for companies that can demonstrate improved patient outcomes and system-wide savings.

To overcome logistical delays, a hybrid lab testing model is effective. It uses local labs for rapid eligibility screening to accelerate patient enrollment, while simultaneously using central labs for standardized, confirmatory validation. This approach balances the need for speed with the requirement for rigorous, reliable data.

Inflammatics initially tried to license its technology but was rejected by major diagnostic firms. The pitch—to build new capabilities and a new platform to displace their own multi-billion dollar microbiology tests—was a classic innovator's dilemma. This refusal by incumbents to disrupt themselves forced the founders to start their own company.

The primary challenge for many MedTech innovations is not the initial science but translating a lab process into a robust, scalable, and GMP-compliant manufacturing system. This requires a shift from proving a concept to ensuring consistent quality and patient safety.

Many companies fail by building a technology and then searching for a problem. VedaBio exemplifies the opposite approach: first defining the "perfect product" for a specific need (urgent care testing), and then applying the right technology to build it.

To scale COVID testing amidst massive shortages, Curative intentionally sourced non-standard supplies (e.g., electronics swabs, different extraction materials) to avoid competing with incumbents for the same scarce resources. This 'orthogonal' approach was key to their hyper-growth from 7 to 7,000 employees in nine months.

Regulatory approval is just an early milestone in diagnostics. True success requires solving for reimbursement, manufacturing scale, supply chain, and commercialization from the very beginning. These non-scientific hurdles are critical for building a viable business.